Education

Biography

Dr. Alexander E Berezin has received PhD in 1994 in the State Medical University of Zaporozhye (Ukraine). He is currently working as a Professor of Medicine in the State Medical University of Zaporozhye (Ukraine). His research goals are fundamental study of biological markers, the development of cardiovascular prevention and rehabilitation. Based on this research and training in heart failure he has received several awards and honors. He has published 850 papers and more in reputed journals, 27 books/chapters and has been serving as an editorial board member of repute.

Research Interest

• The fundamental study of biological markers of cardiovascular and metabolic diseases, heart failure, diabetes mellitus, obesity, endothelial dysfunction, microvesicles, stem cells
• The implementation of visualization procedures and percutaneous cardiovascular interventions
• The development of cardiovascular prevention and rehabilitation, especially in the field affected heart failure and coronary artery disease, improving knowledge in vascular biology and regenerative medicine.

Scientific Activities

Employment History

Professional Activities

• Member of the Ukrainian Cardiology Association
• Member of the Ukrainian Heart Failure Association
• Member of       Heart Failure Association of the ESC
• member of the ESC Council on Hypertension
• Editor-in-Chief of “Biological Markers and Guided Therapy”, "Diabetes Research and Treatment", "J Stem Cell & Regenerative Biology", “Gavin Journal of Cardiology and Cardiovascular Diseases”, “Precision medicine and public health”, “Biomarkers Journal”, “Gavin International Journal of Genomics and Genomics”, and he is Co-Editor of “BBA Clinical”, “International Journal of Biochemistry & Physiology”, “Biomedical Research and Therapy”.
• Editorial Board Member of the Journal Cardiology and Therapy, Case Reports in Internal Medicine; Pathology; Act Issues Med Pharm; Journal of Disease Markers; Aperito Journal of Pharmacology and Drug Designing; Diabetes Research and Treatment: Open Access; Heart Health; Stem Cell and Translational Investigation
  

Publications

1. Alexander E. Berezin, Alexander A. Kremzer, Tatyana A Berezina, Yulia V. Martovitskaya, Elena A. Gromenko: Relation of osteoprotegerin level and numerous of circulating progenitor mononuclears in patients with metabolic syndrome. 03/2016; 3(2):501-513. DOI:10.7603/s40730-016-0007-7
2. Alexander E Berezin: Berezin AE. Is Global 2D-Strain Able to Be Better Tool for Cardiotoxicity Determination in Cancer Survivors Received Various Chemotherapeutic Agents? J Clin Trial Cardiol. 2016; 3(1): 1-6..
3. Alexander E Berezin: Berezin, A., Kremzer, A., Berezina, T., Martovitskaya, Y., & Gromenko, E. (2016). Relation of osteoprotegerin level and numerous of circulating progenitor mononuclears in patients with metabolic syndrome. Biomedical Research And Therapy, 3(2), 501-513..
4. Alexander E Berezin: Alexander E Berezin (2016), Prognostication of Cardiovascualr Complications in Metabolic Syndrome Patients: The Role of Vistafin. Diabetes Res Treat Open Access 3: 131-136.
5. Alexander E Berezin: Berezin AE, Kremzer AA, Predictive value of circulating osteonectin in patients with ischemic symptomatic chronic heart failure, Biomedical Journal (2016), 1-8 http://dx.doi.org/10.1016/j.bj.2015.08.002.
6. Alexander E Berezin: Berezin AE. Predictive value of vistafin in metabolic syndrome patients: focus on of cardiovascular complications. Biological Markers and Guided Therapy. 2016; 1 (3): 33 – 43.
7. Alexander E Berezin: Berezin A. The Biomarker Utility in Risk Stratification in an Ambulatory Heart Failure: ST2 or Galectin-3? Journal of Cardiology and Therapy 2016; 3(1): 456-458.
8. Alexander E Berezin: Berezin A. E. The Neutrophil Extracellular Traps: The Missed Link between Microvascular Inflammation and Diabetes? Metabolomics. 2016; 6: 163-166. doi:10.4172/2153-0769.1000163. Metabolomics 01/2016; 6(1):163-166. DOI:10.4172/2153-0769.1000163
9. Alexander E Berezin: Alexander E. Berezin, Alexander A. Kremzer, Yulia V. Martovitskaya, Tatyana A. Berezina, Elena A. Gromenko. Pattern of endothelial progenitor cells and apoptotic endothelial cell-derived microparticles in chronic heart failure patients with preserved and reduced left ventricular ejection fraction. EBioMedicine. 2016; doi: 10.1016/j.ebiom.2016.01.018. EBioMedicine 01/2016; 4:86-94. DOI:10.1016/j.ebiom.2016.01.018
10. Alexander E Berezin: Berezin A (2016) The Rationality to Use of Galectin-3 as Target in Biomarker-Guided Therapy of Type 2 Diabetes Mellitus. Endocrinol Metab Syndr 5: 1000217. doi:10.4172/2161-1017.1000217.
11. Alexander E Berezin: Berezin AE. Is rationale to decrease serum osteoprotegerin and fetuin-A in type 2 diabetes mellitus patients? Diabetes & Metabolic Syndrome: Clinical Research & Reviews; 2016 [ahead of print]. Diabetes and Metabolic Syndrome Clinical Research and Reviews 01/2016;
12. Alexander Berezin: Is rationale to decrease serum osteoprotegerin and fetuin-A in type 2 diabetes mellitus patients?. Diabetes and Metabolic Syndrome Clinical Research and Reviews 01/2016; DOI:10.1016/j.dsx.2016.01.008
13. Alexander E Berezin: Berezin AE. Does Visfatin Predict Cardiovascular Complications in Metabolic Syndrome Patients? Endocrinol Metab Syndr. 2016; 5: 224-227. doi:10.4172/2161-1017.1000224.
14. Alexander E Berezin: Berezin AE (2016) Aortic Stenosis: Predictive Value of Cardiac Biomarkers in Older Patients. J Gerontol Geriatr Res 5: 263. doi:10.4172/2167-7182.1000263.
15. Alexander E Berezin: Berezin AE. Early Tumoricidal Drug-Induced Cardiotoxicity Determination: Possibilities of Biological Markers.Biological Markers and Guided Therapy, Vol. 2, 2015, no. 1, 143-151.
16. Alexander E. Berezin, Alexander A. Kremzer, Giovanni Cammarota, Anthony Zulli, Daniel Petrovic, Nieves Martell-Claros, Jan Sabo, Peter Kruzliak: Circulating endothelial-derived apoptotic microparticles and insulin resistance in non-diabetic patients with chronic heart failure.. Clinical Chemistry and Laboratory Medicine 12/2015;
17. Alexander E Berezin: Berezin AE. The Biosensing of Microparticles: Benefits and Perspectives. ARC Journal of Diabetes and Endocrinology. 2015; 1(1): 31-34.
18. Alexander E Berezin, Alexander A Kremzer: Alexander E. Berezin, Alexander A. Kremzer (2015) Signature of circulating endothelial-derived progenitor cells in patients with metabolic syndrome and diabetes mellitus. Biological Markers and Guided Therapy, Vol. 2, no. 1, 113-135. http://dx.doi.org10.12988bmgt.2015.51211.
19. Gregoriy А. Igtatenko, Olga S. Nalotova, Alexander Е. Berezin: Gregoriy А. Ignatenko, Olga S. Nalotova, Alexander Е. Berezin. The fixed combination of aliskiren and nebivolol in hypertensive patients: the clinical perspectives. Biological Markers and Guided Therapy. 2015;. 2 (1): 107 - 111.
20. Alexander E Berezin: Berezin AE (2015) Cardiovascular Biomarkers in Routine Screening of Diabetic Patients. Clin Med Biochemistry Open Access 1: 107-112. doi:10.4172/cmbo.1000107.
21. Alexander E Berezin: Berezin AE. Predicting Heart Failure Phenotypes using Cardiac Biomarkers: Hype and Hope. JDisMarkers. 2015; 2(4): 1035-1041..
22. AlexanderEBerezin: Березин А.Е. Протеины внеклеточного матрикса как биомаркеры васкулярного ремоделирования и кардиоваскулярных клинических исходов. Укр. мед. часопис. 2015; 6 (110): 58-64.
23. Alexander E Berezin: Berezin A, Kremzer A, Berezina T, Martovitskaya Y, Gronenko O (2015) The Pattern of Circulating Microparticles in Diabetes Mellitus Patients with Known Subclinical Atherosclerosis. Clin Med Biochemistry Open Access 1: 104-110. doi:10.4172/cmbo.1000104.
24. Alexander E Berezin: Berezin AE. Prognostication of Early Cardio toxicity in Anti-Neoplastic Chemotherapy: The Role of Biological Markers. Heart Health Open Access; 2015; 2:116-120.. Open Access Journal of Contraception 11/2015; 2:116-120. DOI:10.14437/2378
25. Alexander E Berezin: Berezin AE. Can Fibroblast Growth Factor-23 Improve Prognostication in Heart Failure Patients? Austin J Cardiovasc Dis Atherosclerosis. 2015; 2(2): 1015-1016.
26. Alexander E Berezin: Berezin AE, Kremzer AA, Berezina TA, Martovitskaya Yu V. An association of insulin resistance with numerous of circulating microparticles originated from endothelial cells in cardiac failure individuals without history of diabetes mellitus. J Dis Markers. 2015; 2(4): 1032-1041.
27. N.V. Sergienko, E.N. Nalotova, A. E. Berezin: N.V. Sergienko, E.N. Nalotova and A. E. Berezin. Dynamics of biochemical markers in patients suffering from heart failure, under the influence of cell therapy. Biological Markers and Guided Therapy. 2015; 2 (1): 49 – 61.
28. Alexander E Berezin: Berezin AE. Prognostication of heart failure development and advance: the role of high-sensitive ST2. Integr Mol Med. 2015; 2(6): 426-427 doi: 10.15761/IMM.1000180.
29. Alexander E Berezin, Alexander A Kremzer, Tatayna A Samura: Predictive Value of Circulating VE-catherin in Coronary Artery Disease Patients with Symptomatic Moderate to Severe Chronic Heart Failure. Journal of Medicine 11/2015; 16(2):73. DOI:10.3329/jom.v16i2.25430
30. Alexander E Berezin: Berezin AE. The Myeloid-Related Protein Complex Calprotectin as Biomarker of Cardiovascular Risk in Diabetes Mellitus Patients. Diabetes Res Treat Open Access. 2015; 2:129-135.
31. Alexander E Berezin: Berezin AE. Circulating Cell-Free Mitochondrial DNA as Biomarker of Cardiovascular risk: New Challenges of Old Findings. Angiology. 2015; 3: 161-164. doi:10.4172/2329-9495.100016. Angiology 11/2015; 3:161-164. DOI:10.4172/2329-9495.100016
32. Alexander E Berezin, Alexander A Kremzer, Yulia V Martovitskaya, Tatyana A Samura, Tatyana A Berezina, Anthony Zulli, Jan Klimas, Peter Kruzliak: The utility of biomarker risk prediction score in patients with chronic heart failure. International Journal of Clinical and Experimental Medicine 10/2015; 8(10):18255-18264. DOI:10.1186/s40885-016-0041-1
33. Alexander E. Berezin: Endothelial Derived Micro Particles: Biomarkers for Heart Failure Diagnosis and Management.
34. Alexander E Berezin: Berezin AE, Kremzer AA, Martovitskaya YV, Samura TA, Berezina TA, Zulli A, Klimas J, Kruzliak P. The utility of biomarker risk prediction score in patients with chronic heart failure. Int J Clin Exp Med. 2015; 8(10):18255-64. International Journal of Clinical and Experimental Medicine 10/2015; 8(10):18255-64.
35. Alexander E Berezin: Berezin AE, Kremzer AA, Berezina TA, Martovitskaya Yu V. The pattern of circulating microparticles in patients with diabetes mellitus with asymptomatic atherosclerosis. Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine. 2015 [ahead of print].
36. Alexander E Berezin: Berezin AE, Kremzer AA, Samura TA. GLOBAL LONGITUDINAL STRAIN AND STRAIN RATE IN CHRONIC HEART FAILURE PATIENTS WITH DIABETES MELLITUS. the XXI. World Congress of Echocardiography and Cardiology – ISCU 2015.
37. Alexander E Berezin: Berezin AE. Diabetes mellitus related biomarker: the predictive role of growth-differentiation factor-15. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2015 [ahead of print] Doi: 10.1016/j.dsx.2015.09.016. Diabetes and Metabolic Syndrome Clinical Research and Reviews 10/2015; DOI:10.1016/j.dsx.2015.09.016
38. Alexander E Berezin: Berezin AE, Kremzer AA. Сirculating osteonectin as predictive biomarker in patients with ischemic symptomatic chronic heart failure. International Cardivascular Research Journal. 2015; 9(4): 203-209 doi: 10.17795/icrj-9(4)203. International Cardiovascular Research Journal 10/2015; 9(4):203-209. DOI:10.17795/icrj-9(4)203
39. Berezin AE, Medvedkova SA: Medvedkova SA, Berezin AE (2015) Vascular Endothelial Growth Factor-1 Level and Functional Neurologic Recovery after Ischemic Hemispheric Stroke. Neurochem Neuropharm Open Access 1: 102-105. doi:10.4172/ncoa.1000102.
40. Alexander E Berezin: Berezin AE. Stable Coronary Artery Disease Patients: Different Practice Patterns in Everyday Clinical Situations. E-Biomedicine. 2015 [ahead of print] Doi:10.1016/j.ebiom.2015.10.007.
41. Alexander E Berezin: Berezin AE. The Role of Cardiac Biomarkers in Predicting of Mortality in Diabetic Patients. Journal of Cardiol Ther 2015 October 2(5): 273-278.
42. Alexander E Berezin, Alexander A Kremzer, Tatyana A Berezina, Yulia V Martovitskaya: Berezin AE, Kremzer AA, Berezina TA, Martovitskaya Yu V (2015) The Immune Phenotypes of Circulating Microparticles in Patients with Diabetes Mellitus: Relevance to Serum Galectin-3 Level. JDiabRelDis 1(1): 101..
43. Alexander E Berezin: Berezin AE. Are Endothelial Cell-Derived Microparticles Predictive Biomarkers in Cardiovascular Diseases?. Atherosclerosis: open access. 2015; 1: e101-e103. doi:10.4172/asoa.1000e101. Atherosclerosis 09/2015; 1:101-103. DOI:10.4172/asoa.1000e101
44. Alexander E Berezin: Berezin AE. Growth-differentiation factor-15 at risk stratification in diabetes patients: usefulness, discrepancies, and hype. Int Arch Endocrinol Clin Res. 2015; 1: 2-5.
45. Alexander E Berezin: Alexander E. Berezin; Alexander A. Kremzer; Yulia V. Martovitskaya; Tatyana A. Samura; Tatyana A. Berezina. The Association of Subclinical Hypothyroidism and Pattern of Circulating Endothelial-Derived Microparticles Among Chronic Heart Failure Patients. Res Cardiovasc Med. 2015 November; 4(4): e29094.
46. Alexander E. Berezin, Alexander A. Kremzer, Yulia V. Martovitskaya, Tatyana A. Samura, Tatyana A. Berezina: The Association of Subclinical Hypothyroidism and Pattern of Circulating Endothelial-Derived Microparticles Among Chronic Heart Failure Patients. 09/2015; 4(4). DOI:10.5812/cardiovascmed.29094
47. Alexander E Berezin, Alexander A Kremzer, Yulia V Martovitskaya, Tatyana A Samura, Tatyana A Berezina: Pattern of circulating endothelial-derived microparticles among chronic heart failure patients with dysmetabolic comorbidities: The impact of subclinical hypothyroidism. 08/2015; DOI:10.1016/j.dsx.2015.08.001
48. Alexander E Berezin: Berezin AE. A Limited Effect of High-Sensitive ST2 on Risk Stratification in Heart Failure Patients. J Cardiovasc Disord. 2015; 2(2): 1014-1016.
49. Alexander E Berezin: Berezin AE (2015) Endothelial Derived Micro Particles: Biomarkers for Heart Failure Diagnosis and Management. J Clin Trial Cardiol 2(3): 1-3.
50. Alexander E Berezin: Berezin AE. Impaired Phenotype of Circulating Endothelial-Derived Microparticles: Novel Marker of Cardiovascular Risk. Journal of Cardiology and Therapy 2015; 2(2): 273-278. 08/2015; 2(2):273-278. DOI:10.17554/j.issn.2309-6861.2015.02.77
51. Alexander E Berezin, Alexander A. Kremzer, Berezina YA, Martovitskaya YuV: Berezin AE, Kremzer AA, Berezina YA, Martovitskaya YuV. Pattern of circulating microparticles in chronic heart failure patients with metabolic syndrome: relevance to neurohumoral and inflammatory activation. BBA Clinical (2015), pp. 69-75. Biochimica et Biophysica Acta - Clinical 08/2015; 4:69-75. DOI:10.1016/j.bbacli.2015.07.002
52. Alexander E Berezin, Alexander A Kremzer: Analysis of Various Subsets of Circulating Mononuclear Cells in Asymptomatic Coronary Artery Disease. Journal of Clinical Medicine 08/2015; 2(3):32-44. DOI:10.3390/jcm2030032
53. Alexander E Berezin: Alexander Berezin (2015) Utility of Biomarkers in Contemporary Management of Chronic Heart Failure. Annals of Clinical and Laboratory Research. 3 (2): 16-28..
54. Alexander E Berezin: Berezin A E (2015) The Development of Biological Molecular Sensing Techniques to detect Micro particles: Focus on Clinical Medicine Benefits. J Microb Biochem Technol 7:4 235-236.. Journal of Microbial & Biochemical Technology 07/2015; 7(4):235-236. DOI:10.4172/1948-5948.1000214
55. Olga S. Nalyotova, ergey N. Lyaschuk, Alexander E. Berezin, Sergey V. Nalyotov: Olga S. Nalyotova, Sergey N. Lyaschuk, Alexander E. Berezin, Sergey V. Nalyotov. Chemical interactions between molecules of both aliskiren and nebivolol in combined application. World Journal of Pharmaceutical and Life Sciences. 2015; 1 (2): 121-128. International Journal of Pharmaceutical and Life Sciences 07/2015; 1(2):121-128.
56. Alexander E Berezin: Angiology: Open Access. Angiology 07/2015; 3(3):145-149. DOI:10.4172/2329-9495.1000145
57. Alexander E Berezin: Berezin AE, Kremzer AA, Martovitskaya YuV, Samura TA, Berezina TA. Novel heart failure risk prediction score based on biomarker measurements: clinical approach and comparable utility. Danish Journal of Medical and Biology Sciences , July, 2015, Pages: 58-70 http://dx.doi.org/10.6084/m9.figshare.1487698.
58. Alexander E Berezin: Berezin AE. Matricellular proteins as biomarkers of vascular remodelling and cardiovascular clinical outcomes. Ukr Med J. 2015; 4.
59. Alexander E Berezin: Alexander E Berezin. Is Elevated Circulating Level of Galectin-3 A Marker with Diagnostic and Predictive Value in Diabetic Patients? Heart Health Open Access. 2015; 2:110-116.
60. Alexander E Berezin: Berezin AE, Kremzer AA. The predictive role of circulating microparticles in patients with chronic heart failure. Journal of Hypertension, 2015; 33, p.e463. doi: 10.1097/01.hjh.0000468841.80707.69. Journal of Hypertension 06/2015; 33. DOI:10.1097/01.hjh.0000468841.80707.69
61. Alexander E Berezin: Berezin AE, Kemzer AA. INTERRELATIONSHIP BETWEEN INSULIN RESISTANCE, INTEGRATED SYSTOLIC AND DIASTOLIC FUNCTION OF LEFT VENTRICLE IN CHRONIC HEART FAILURE PATIENTS. J Hypertension. 2015; 33, p.e463. doi: 10.1097/01.hjh.0000468842.80707.b2. Journal of Hypertension 06/2015; 33:p.e463. DOI:10.1097/01.hjh.0000468842.80707.b2
62. Alexander E Berezin: Berezin AE. Vascular Remodelling and Cardiovascular Outcomes. Predictive Role of Matricellular Proteins. Autoimmune Dis Ther Approaches. 2015; 2:115-129. Doi: 0.14437/2378-6337-2-115.
63. Alexander E Berezin: The Impact of Low-Grading Inflammation on Circulating Endothelial-Derived Progenitor Cells in Patients with Metabolic Syndrome and Diabetes Mellitus.
64. Alexander E Berezin: Berezin AE. DIHYDROPYRIDINE DERIVATIVES OF CALCIUM CHANNELS BLOCKER AND FIXED COMBINATION BASED ON CALCIUM CHANNELS BLOCKERS IN THE TREATMENT OF HYPERTENSIVE PATIENTS. Ukr Med J. 2015. 3.
65. Alexander E Berezin: Berezin AE, Kremzer AA, Berezina TA, Martovitskaya YV (2015) The Impact of Low-Grading Inflammation on Circulating Endothelial-Derived Progenitor Cells in Patients with Metabolic Syndrome and Diabetes Mellitus. J Endocrinol Diab 2(3): 8-18.
66. A.E. Berezin Berezin, A.A. Kremzer Kremzer: Content of Circulating Endothelial Progenitor Cells in Patients With Chronic Ischemic Heart Failure With Preserved Left Ventricular Ejection Fraction. Kardiologiia 06/2015; 55(1):14-22. DOI:10.18565/cardio.2015.1.14-22
67. Alexander E Berezin: Berezin AE. Matricellular Proteins as Biological Markers in Vascular Remodelling and Cardiovascular Outcomes. J Dis Markers. 2015;2(2): 1025
68. Berezin, A. Kremzer: The predictive role of the pattern of endothelial-derived microparticles in heart failure patients. European Journal of Cardiovascular Nursing 06/2015; 14:S78-S78.
69. Alexander E. Berezin, Alexander A. Kremzer: Predictive value of circulating osteonectin in patients with ischemic symptomatic moderate-to-severe chronic heart failure. European Journal of Cardiovascular Nursing 06/2015; 14:S10-S11. DOI:10.1016/j.bj.2015.08.002
70.  A. Berezin, A. Kremzer: Predictive role of osteoprotegerin in coronary vasculature damage among patients with type two diabetes mellitus. European Journal of Cardiovascular Nursing 06/2015; 14:S36-S37.
71. Alexander E Berezin: Berezin AE, Kremzer AA, Berezina TA, Martovitskaya YuV (2015) The association of serum osteoprotegerin/ sRANKL complex, C-reactive protein and adiponectin with number of circulating endothelial progenitor cells in patients with metabolic syndrome and diabetes mellitus. J Integr Cardiol, 1 (3): DOI: 10.15761/JIC.1000121.
72. T Sharir, M Pinskiy, B Brodkin, A Rochman, V Prochorov, A Bojko, K Merzon, A Pardes, A A Ghotbi, P Hasbak, T Christensen, T Engstroem, M Lassen, A A Kjaer, E Ficaro, V L Murthy, J R Corbett, O Zoccarato, C Marcassa, R Matheoud, A Savi, L Indovina, S Ren Kaiser, M J Bom, P M Van Der Zee, J H Cornel, F M Van Der Zant, Rjj Knol, M N Pizzi, A Roque, N Fernandez-Hidalgo, H Cuellar-Calabria, M T Gonzalez-Alujas, G Oristrell, J Rodriguez-Palomares, P Tornos, S Aguade-Bruix, A Berezin, A Kremzer, M Gautier, D Legallois, A Belin, D Agostini, A Manrique: Moderated Poster Session 2: Sunday 3 May 2015, 15:30-16:30Room: Moderated Poster Area. European Heart Journal Cardiovascular Imaging 05/2015; 16 Suppl 1:i8-i10. DOI:10.1093/ehjci/jev048
73. Berezin AE, Kremzer AA, Samura TA, Berezina TA, Kruzliak P: Impaired immune phenotype of circulating endothelial-derived microparticles in patients with metabolic syndrome and diabetes mellitus.. Journal of endocrinological investigation 04/2015;
74. A E Berezin, A A Kremzer, T A Samura, T A Berezina, P Kruzliak: Impaired immune phenotype of circulating endothelial-derived microparticles in patients with metabolic syndrome and diabetes mellitus. Journal of endocrinological investigation 04/2015; 38(8). DOI:10.1007/s40618-015-0273-z
75. Alexander E Berezin: Berezin AE, Kremzer AA. Article title: Impaired phenotype of circulating endothelial microparticles in chronic heart failure patients: relevance to body mass index. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2015; [in press] DOI information: 10.1016/j.dsx.2015.04.003. Diabetes and Metabolic Syndrome Clinical Research and Reviews 04/2015;
76. Alexander E. Berezin, Alexander A. Kremzer: Impaired phenotype of circulating endothelial microparticles in chronic heart failure patients: Relevance to body mass index. Diabetes and Metabolic Syndrome Clinical Research and Reviews 04/2015; DOI:10.1016/j.dsx.2015.04.003
77. Alexander E Berezin: Alexander E. Berezin and Alexander A. Kremzer. The predictive role of circulating microparticles in patients with chronic heart failure. J Extracell Vesicles. 2015; 4: PVIII-14. doi: 10.3402/jev.v4.27783.
78. Alexander E Berezin: Berezin AE, Kremzer AA, Samura TA, Martovitskaya YuV, Berezina TA. Interrelationship between insulin resistance and impaired immune phenotype of circulating endothelial-derived microparticles in none-diabetic patients with chronic heart failure. J Integr Cardiol. 2015; 1(2): 35-40..
79. Alexander E Berezin: Alexander E Berezin, Alexander E Kremzer. Inflammatory phenotype of circulating endothelial-derived microparticles in chronic heart failure patients with metabolic syndrome. Journal of Molecular Pathophysiology 2015, 4(2): 51-58.
80. Alexander E Berezin: Berezin AE, Kremzer AA, Samura TA (2015) The predictive role of various phenotypes of circulating endothelial-derived microparticles in patients with chronic heart failure: results of prospective study. Heart and vessels. 1(49).
81. Alexander E Berezin: Berezin AE, Kremzer AA, Samura TA (2015) Circulating Osteoprotegerin as Predictor of Global Systolic Dysfunction in Type Two Diabetes Patients with Chronic Heart Failure. J Res Development. 3: 121. doi:10.4172/jrd.1000121.
82. Alexander E Berezin: Berezin AE, Kremzer AA, Samura TA. Circulating thrombospondine-2 in patients with moderate-to-severe chronic heart failure due to coronary artery disease. Journal of Biomedical Research. 2015. [ahead of print] doi: 10.7555/JBR.29.20140025.
83. Alexander E Berezin: Immune Phenotype of Circulating Endothelial-derived Microparticlesin Elderly Patients with Metabolic Syndrome and Diabetes Mellitus. 02/2015; 04(01). DOI:10.4172/2167-7182.1000199
84. Alexander Berezin, Anthony Zulli, Steve Kerrigan, Daniel Petrovic, Peter Kruzliak: Predictive Role of Circulating Endothelial-derived Microparticles in Cardiovascular Diseases. Clinical Biochemistry 02/2015; 48(9). DOI:10.1016/j.clinbiochem.2015.02.003
85. Berezin A, Zulli A, Kerrigan S, Petrovic D, Kruzliak P: Predictive Role of Circulating Endothelial-derived Microparticles in Cardiovascular Diseases.. Clinical Biochemistry 02/2015;
86. Alexander E Berezin: Berezin AE, Kremzer AA. The predictive role of different phenotypes of circulating microparticles in patients with chronic heart failure. EUROPEAN JOURNAL OF HEART FAILURE. 2015; 17: 269-269.. European Journal of Heart Failure 01/2015; 17:269.
87. Alexander E. Berezin, Alexander A. Kremzer, Giovanni Cammarota, Anthony Zulli, Daniel Petrovic, Nieves Martell-Claros, Jan Sabo, Peter Kruzliak: Circulating endothelial-derived apoptotic microparticles and insulin resistance in non-diabetic patients with chronic heart failure. Clinical Chemistry and Laboratory Medicine 01/2015; DOI:10.1515/cclm-2015-0605
88. Alexander E Berezin: Berezin AE (2015) Impaired Pattern of Endothelial Derived Microparticles in Heart Failure Patients. J Mol Genet Med 9: 152. doi: 10.4172/1747-0862.1000152.
89. Svetlana A Medvedkova, Alexander E Berezin: Vascular Endothelial Growth Factor-1 Level and Functional Neurologic Recovery after Ischemic Hemispheric Stroke.
90. Alexander E. Berezin: Impaired Phenotype of Circulating Endothelial-Derived Microparticles: Novel Marker of Cardiovascular Risk. 01/2015; 2(4):365-370. DOI:10.17554/j.issn.2309-6861.2015.02.78
91. Alexander E. Berezin: Circulating Cell-Free Mitochondrial DNA as Biomarker of Cardiovascular risk: New Challenges of Old Findings.
92. Alexander E Berezin: The Metabolic Effects of Mineralocorticoid Receptor Antagonists in Heart Failure Patients.
93. Alexander Berezin, Alexander Kremzer, Tatyana Samura, Tatyana Berezina: Inflammatory phenotype of circulating endothelial-derived microparticles in chronic heart failure patients with metabolic syndrome. 01/2015; 4(2). DOI:10.5455/jmp.20150402063644
94. Alexander E Berezin: Immune Phenotypes of Endothelial-Derived Microparticles in Dysmetabolic Patients.. Journal of Proteomics & Bioinformatics 01/2015; 08(03). DOI:10.4172/jpb.1000353
95. Alexander E Berezin: Micro RNA as Biomarkers and Tool for Target-Based Treatment in Patients with Inflammatory Bowel Diseases. Biology and Medicine 01/2015; 07(02). DOI:10.4172/0974-8369.1000231
96. Alexander E Berezin: Berezin AE, Kremzer AA. Content of Circulating Endothelial Progenitor Cells in Patients With Chronic Ischemic Heart Failure With Preserved Left Ventricular Ejection Fraction. Cardiology. 2015; 1: 14-22.. Cardiology 01/2015; 1:14-22.